40. 高安動脈炎 Takayasu arteritis Clinical trials / Disease details
臨床試験数 : 25 / 薬物数 : 50 - (DrugBank : 21) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 114
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05151848 (ClinicalTrials.gov) | January 5, 2022 | 6/11/2021 | Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis | An Open-label,Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis | Takayasu Arteritis | Drug: Adalimumab Injection;Drug: Tofacitinib 5 MG | Chinese SLE Treatment And Research Group | NULL | Recruiting | 18 Years | 65 Years | All | 100 | Phase 4 | China |